Figure 1.

AK045171 was downregulated in cardiomyocytes and myocardium subjected to AngII and TAC treatment. (A) Haematoxylin and eosin staining of the heart under sham and TAC treatment to investigate the size of the heart and cardiomyocytes. (B, C) Echocardiographic parameters of the mice, including LVEDP, LVFS, LVEF, LVESD, were evaluated with an ultrasound system. (D) Quantification of the heart weight-to-tibial length ratio. (E) Masson staining was used to detect myocardial fibrosis. (F) Immunostaining for α-SMA was used to evaluate the size of cardiomyocytes subjected to AngII treatment or not. (G) The level of the myocardial hypertrophy biomarkers ANP, BNP and β-MHC were detected using qPCR. (H, I) The expression of AK045171 was detected with qPCR. *p<0.05 vs control or sham group.